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Background: Obstructive sleep apnea syndrome (OSAS) and chronic kidney disease 
(CKD) are common diseases encountered in primary care. These diseases share the 
same pathophysiology of chronic inflammation. In recent years, it was reported that the 
inflammasome participates in chronic inflammation, and interleukin (IL)-18 has 5 
received significant attention as an inflammasome marker. IL-18 is also closely 
associated with renal function, and is a stronger predictive marker of renal function 
disorder than high-sensitivity C-reactive protein (hsCRP) or IL-6. OSAS is also 
reported to be an independent risk factor of CKD. However, other basal diseases 
associated with OSAS and severe renal function disorders may also be CKD risk factors, 10 
such as hypertension, diabetes mellitus, and hyperlipidemia. So it should be carefully 
interpreted. Therefore, we investigated renal function in OSAS patients with no 
potentially confounding disorders using IL-18. 
Methods: We assessed OSAS severity (apnea–hypopnea index [AHI]); renal function 
(estimated glomerular filtration rate); and hsCRP, IL-6, and IL-18 levels in 23 patients 15 
newly diagnosed with OSAS and free from other diseases  
Results: Serum levels of IL-18 demonstrated a significant negative correlated with 




Conclusions: Even when renal dysfunction is mild, chronic inflammation is present in 
OSAS patients. We hypothesize that IL-18 is a useful marker to detect chronic 
inflammation in OSAS patients and that this chronic inflammation contributes to CKD. 
These results suggest that IL-18 is an associative marker for OSAS and renal function 
disorder, and can help achieve early treatment intervention in primary care. 5 
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Obstructive sleep apnea syndrome (OSAS) and chronic kidney disease (CKD) are 
common diseases encountered in primary care. Chronic inflammation, caused by 
oxidative stress and endothelial cell dysfunction, represents a common pathophysiology 
between OSAS and CKD. Chronic inflammation has already been recognized as an 5 
important factor in cardio-renal association, whereby even a slight disorder in renal 
function can be a risk factor for cardiovascular disease (CVD). Chronic inflammation is 
closely involved in arteriosclerosis and can be identified by high-sensitivity C-reactive 
protein (hsCRP), which is produced by interleukin-6 (IL-6) acting on the liver. Elevated 
hsCRP and IL-6 are predictive markers of cardiovascular events1–3. In recent years, 10 
interleukin-18 (IL-18) has also been proposed as such a marker. IL-18 has a closer 
association with renal function, and is also a better predictive marker of renal function 
disorder than hsCRP or IL-6 without influence of the creatinine clearance4, 5. 
In addition, IL-18 is closely associated with chronic inflammation. In recent studies, it 
was reported that the inflammasome participates in chronic inflammation. 15 
Inflammasomes are large intracellular multiprotein complexes that play a central role in 
chronic inflammation and form in response to bacteria and stress signals. Activated 




cytokines are involved in host defense against pathogen infections6-8 . In recent years, 
these cytokines have been established to play an important role in lifestyle-related 
diseases, such as CKD and arteriosclerotic diseases. There are many reports indicating 
the association between such diseases and cytokines that are derived from 
inflammasomes9, 10 . IL-18 is derived directly from inflammasomes, while hsCRP and 5 
IL-6 are downstream targets of IL-1β. Thus, IL-18 is more useful for the evaluation of 
chronic inflammation and renal function disorder.  
On the other hand, recent studies reported increased CKD in OSAS patients11, 12 . The 
findings of these studies should be carefully interpreted, since basal diseases that are 
easily complicated with OSAS and severe renal function disorders can be independent 10 
risk factors of CKD, including hypertension, diabetes mellitus, and hyperlipidemia. 
OSAS is not only a disease to cause simple sleepiness, but also causes arteriosclerotic 
disease and coronary artery diseases13 . In primary care, it has big significance to clear 
the association OSAS and CKD, and the cytokine senses them. This study was 
conducted to assess the association OSAS and renal function disorders in OSAS patient 15 







Fifty-three men and thirteen women with newly diagnosed OSAS (age 20-75 years) in 
2001 to 2009 were enrolled in this study (Table 1). Their baseline characteristics were 
recorded, and they underwent polysomnography. Forty-three participants had other 
diseases including hypertension, diabetes mellitus, and hyperlipidemia. Sixteen men and 5 
seven women with newly diagnosed OSAS (age 24-72 years) in 2001 to 2009 were 
extracted from all patients (Table 2). Their baseline characteristics were recorded, and 
they underwent polysomnography. All participants were free from other diseases 
including hypertension, diabetes mellitus, and hyperlipidemia and were taking no 
medications. This study was approved by the Ethics Committee of Nagasaki University 10 
Hospital, and all participants provided informed consent. 
 
Polysomnography  
Full polysomnographic monitoring was performed with the EMBLA S7000 system 
(Chest Co., Ltd., Fukuoka, Japan). An AHI score greater than 5/hour in conjunction with 15 
sleep-related symptoms was considered diagnostic of OSAS. AHI ≥ 5 and < 20 
indicated mild OSAS, AHI ≥ 20 and < 30 indicated moderate OSAS, and AHI ≥ 30 





We obtained blood samples early in the morning after an overnight fast subsequent to a 
day of full polysomnographic monitoring. Samples of peripheral venous blood were 
collected and stored at −40°C until the time of assay. Serum creatinine was measured by 
enzymatic method, and serum IL-6 was measured by chemiluminescent enzyme 5 
immuno assay (CLEIA) and IL-18 was measured by enzyme-linked immunosorbent 
assay (ELISA). Nephelometric immunoassay was used to measure serum hsCRP. 
Estimated glomerular filtration rate (eGFR) was calculated by the following formula14: 
eGFR = 194 × standardized Scr-1.094 × Age-0.287 (× 0.739[if female]). eGFR ≥ 90 
indicated CKD stage G1, eGFR ≥ 60 and < 89 indicated CKD stage G2, eGFR ≥ 30 and 10 
< 59 indicated CKD stage G3, eGFR ≥ 15 and < 29 indicated CKD stage G4, and eGFR 
< 14 indicated CKD stage G5. Serum creatinine was measured by standard procedures. 
In this study, all patients corresponded to CKD stage G1 and G2. 
 
Statistical analysis  15 
Data are expressed as mean ± SD, and P values <0.05 were considered significant. The 
significance of differences between groups was analyzed by t test and one-way ANOVA. 




correlation coefficient. All statistical analyses were performed using EZR (Saitama 
Medical Center, Jichi Medical University), which is a graphical user interface for R 
(The R Foundation for Statistical Computing, version 2.13.0)15 . 
 
RESULTS 5 
Patients with complications 
All patients’ background characteristics are summarized in Table 1. All patients were 
CKD stage G1–G3. At CKD stage G1, there were eleven men and one woman. 
Hypertension accounted for 18.2% of their complications, diabetes mellitus for 45.5%, 
and hyperlipidemia for 18.2%. At CKD stage G2, there were 36 men and 11 women. 10 
Hypertension accounted accounts for 48.9% of their complications, diabetes mellitus for 
19.1%, and hyperlipidemia for 14.9%. At CKD stage G3, there were seven men and one 
woman. Hypertension accounted for 87.5% of their complications, and diabetes mellitus 
for 37.5%. All patients had mild to severe OSAS. Fourteen men and six women had 
mild OSAS. Hypertension accounted for 35% of their complications, diabetes mellitus 15 
for 10%, and hyperlipidemia for 10%. Fifteen men and three women had moderate 
OSAS. Hypertension accounted for 55.6% of their complications, diabetes mellitus for 




Hypertension accounted for 53.6% of their complications, diabetes mellitus for 21.4%, 
and hyperlipidemia for 39.3%. 
When we examined each cytokine according to stage of CKD or severity of OSAS, we 
did not observe any significant differences across groups. 
 5 
Patients free from other diseases 
The background characteristics of patients free from other diseases are summarized in 
Table 2. These patients had only CKD stage G1–G2. Four men and one woman had 
CKD stage G1, and 12 men and six women had CKD stage G2. The patients’ OSAS 
symptoms ranged from mild to severe. Seven men and five women had mild OSAS, 10 
five men and one woman had moderate OSAS, and four men and one woman had 
severe OSAS. They had no other complications.  
We examined each cytokine according to stage of CKD and severity of OSAS. Serum 
IL-18 levels in patients with CKD stage G1 were significantly lower than those in 
patients with CKD stage G2 (P < 0.05). There was no significant difference in hsCRP or 15 
IL-6. We examined the correlation between each cytokine and eGFR or AHI (Table 3, 
Fig. 1). The only significant relationship observed was a negative correlation between 





Patients per complications 
We compared patients according to whether or not they had complications (Table 4). 
Levels of AHI in patients free from other diseases were significantly lower than those in 




While complications such as basal diseases and renal function disorders were not 
controlled in patients of this study, there was no significant association between 10 
cytokines, including IL-18, and eGFR or AHI. These patients had basal diseases 
including diabetes mellitus. Especially among patients with CKD stage G1, 45.2% 
patients had diabetes mellitus, and some patients’ eGFR levels indicated hyperfiltration. 
Thus, it was not suitable to evaluate the association between eGFR and IL-18. 
Furthermore, these basal diseases that are often found in combination with OSAS can 15 
also be independent risk factors of CKD. In addition, there were CKD stage G3 patients 
in this group. Severe renal function disorders can also be independent risk factors of 




association of OSAS with renal function disorders. Thus, we considered that these 
patients were not suitable for evaluating the association between OSAS and renal 
function. 
Therefore, we considered that the association between OSAS and renal function might 
be apparent in patients when complications and severe renal function disorders are 5 
controlled for. IL-18 might be more suitable to examine the association between OSAS 
and renal function disorders in OSAS patients than previously used cytokines, such as 
hsCRP and IL-6. Serum levels of IL-18 are elevated nonspecifically in many 
pathophysiological conditions and should be interpreted with caution in the presence of 
complications such as lifestyle-related diseases and cardiovascular diseases. We 10 
considered this to be another reason why controlling basal diseases was important. 
 Therefore, we examined patients free from other diseases, among whom we observed a 
significant correlation between eGFR and IL-18. We observed chronic inflammation in 
OSAS patients who were free from other diseases and with mild renal function 
disorders. It should be noted that IL-18 demonstrated a closer association with eGFR 15 
than hsCRP or IL-6. Our results suggest that chronic inflammation is already elicited 
even in mild renal dysfunction that cannot be detected by hsCRP and IL-6, and that 




inflammation from OSAS leads to CKD in the future. These results further indicate that 
IL-18 is an associative marker for OSAS and renal function disorder, and may be useful 
in achieving early treatment intervention in primary care. However, further research is 
necessary to elucidate the mechanism underlying the connection between OSAS and 
CKD onset. 5 
 In this study, we did not demonstrate an association between IL-18 and AHI. IL-18 is 
expected to associate with AHI or eGFR, since OSAS and CKD share the same 
pathophysiology of chronic inflammation. Ideally, the severity of OSAS should be 
determined based not only on AHI score but also on levels of desaturation and clinical 
manifestations. Carpagnano et al. showed that levels of desaturation cause oxidative 10 
stress and inflammation17 . Thus, more research including parameters of desaturation is 
needed.  
 In addition, we found no significant differences among cytokines, renal functions, 
and AHI according to the presence or absence of underlying disease. The 43 patients 
with complications would be expected to demonstrate higher serum levels of cytokines 15 
and lower levels of eGFR. As mentioned previously, some patients’ eGFR levels 






Even when renal dysfunction was mild, chronic inflammation was present in OSAS 
patients. We hypothesize that IL-18 is a useful marker to detect chronic inflammation in 
OSAS patients and that this chronic inflammation is a factor leading to CKD. These 
results suggest that IL-18 is an associative marker for OSAS and renal function disorder, 5 
and may help to achieve early treatment intervention in primary care. 
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Figure 1. Correlation between IL-18 and eGFR 
 
 







Fig.1 :Correlation between IL-18 and eGFR 















Complications, n (%) 
HT DM HL 
eGFR ≧ 90 
(Stage 1 CKD) 
10/1 36.1 ± 9.2 * 30.9 ± 4.7* 41.4 ± 31.7 - 2093.5 ± 2763.1 2.8 ± 1.6  210.5 ± 66.1 2 (18.2) 5 (45.5) 2 (18.2) 
60 < eGFR < 89 
(Stage 2 CKD) 
36/11 54.3 ± 11.7* 27.4 ± 5.1* 29.3 ± 19.8 - 1622.0 ± 2882.8 3.1 ± 2.2 213.1 ± 80.0 23 (48.9) 9 (19.1) 7 (14.9) 
30 < eGFR < 59 
(Stage 3 CKD) 
7/1 62.1 ± 8.9 * 25.2 ± 3.0* 24.1 ± 20.0 - 3794.5 ± 7994.7 3.3 ± 1.6 220.6 ± 65.0 7 (87.5) 3 (37.5) 0 (0) 
Mild OSAS 14/6 52.2 ± 13.7  26.1 ± 3.8* - 76.0 ± 13.9 1592.3 ± 2644.4 2.4 ± 1.2 209.2 ± 70.1 7 (35.0) 2 (10.0) 2 (10.0) 
Moderate OSAS 15/3 56.7 ± 12.0  25.8 ± 3.8* - 68.7 ± 18.1 2672.6 ± 6088.6 3.0 ± 1.8 187.1 ± 58.4 10 (55.6) 1 (5.6) 4 (22.2) 
Severe OSAS  24/4 49.4 ± 13.5  30.2 ± 5.6* - 82.0 ± 19.8 1779.0 ± 2436.3 3.6 ± 2.5 223.7 ± 84.5 15 (53.6) 6 (21.4) 11 (39.3) 
 
eGFR = estimated glomerular filtration rate; AHI = apnea-hypoxia index; hsCRP = highly sensitive C-reactive protein; IL-6 = 
interleukin-6; IL-18 =  interleukin-18; OSAS = obstructive sleep apnea syndrome; CKD = chronic kidney disease; HT = hypertension; 
DM = diabetes mellitus; HC = hyperlipidemia 
Values are mean ± SD 
*P < 0.05 is considered statistically significant 
  
















HT DM HL 
eGFR ≧ 90 
(Stage 1 CKD) 
4/1 32.4 ± 9.8 * 28.8 ± 4.3 * 19.8 ± 10.4 - 677.8 ± 627.7  1.8 ± 0.7  163.6 ± 41.6* - - - 
60 < eGFR < 89 
(Stage 2 CKD) 
12/6 52.9 ± 10.0* 25.0 ± 3.3 * 22.3 ± 21.3  - 1727.9 ± 3066.7  3.0 ± 2.2  216.8 ± 57.5 * - - - 
Mild OSAS 7/5 50.8 ± 15.2  25.5 ± 3.7 - 78.9 ± 12.5 1815.6 ± 3402.8 2.6 ± 1.2 217.7 ± 70.6 - - - 
Moderate OSAS 5/1 46.7 ± 12.3 25.4 ± 3.2 - 79.1 ± 13.5 553.2 ± 516.8 1.8 ± 0.3 173.8 ± 35.7 - - - 
Severe OSAS  4/1 45.0 ± 8.9 27.5 ± 5.0 - 81.8 ± 8.9 1877.2 ± 2728.5 4.4 ± 3.8 213.2 ± 35.4 - - - 
 
eGFR = estimated glomerular filtration rate; AHI = apnea-hypoxia index; hsCRP = highly sensitive C-reactive protein; IL-6 = 
interleukin-6; IL-18 =  interleukin-18; OSAS = obstructive sleep apnea syndrome; CKD = chronic kidney disease; HT = 
hypertension ; DM = diabetes mellitus ; HC = hyperlipidemia 
Values are mean ± SD 
*P < 0.05 is considered statistically significant 
 
Table 3: Spearman's rank correlation coefficient 
 IL-18 hsCRP IL-6 
eGFR -0.49* -0.21 -0.28 
AHI -0.14 0.09 0.27 
 
*P < 0.05 is considered statistically significant 
 
Table 4: Characteristics and biochemical markers of the patients 















HT DM HC 
Patients with complications 37/6 54.7 ± 12.9 35.2 ±22.9* 74.8 ± 21.2  2273.2 ± 4337.9  3.3  ± 2.0 219.1 ± 84.0  12 14 14 
Patients free from other diseases 16/7 47.8 ± 13.1 22.8 ± 19.6* 79.7 ± 11.4 1450.0 ± 2695.7  2.7 ± 2.0 203.8 ± 57.3 none none none 
 
eGFR = estimated glomerular filtration rate; AHI = apnea-hypoxia index; hsCRP = highly sensitive C-reactive protein; IL-6 = 
interleukin-6; IL-18 =  interleukin-18; OSAS = obstructive sleep apnea syndrome; HT = hypertension ; DM = diabetes mellitus ; HC = 
hyperlipidemia 
Values are mean ± SD 
*P < 0.05 is considered statistically significant 
 
